Gross Margin
Euroespes SA

51.7%
Current
76%
Average
44.3%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
51.7%
=
Gross Profit
1.7m
/
Revenue
3.3m

Gross Margin Across Competitors

No Stocks Found

Euroespes SA
Glance View

EuroEspes SA engages in the provision of biomedical services. The company is headquartered in Bergondo, La Coruna. The company went IPO on 2012-06-21. The firm operates a medical center, which focuses on the prevention, diagnosis and treatment of central nervous system disorders, such as Alzheimer and Parkinson, and other common diseases. The Company’s medical offer includes personalized treatment plans, genomic medicine, epigenetics, neuropsychology, neuro-ophthalmology, digital diagnosis, diagnostic imaging, clinical analysis and nursing services, among others. In addition, it provides pharmacogenetics services and Human Identification Genetics card, which identifies user's deoxyribonucleic acid (DNA) profile. The firm operates through a number of subsidiaries, such as in Euroespes Biotecnologia SA, Distribuidora de Productos SL and Ebiotec Pharma SL.

EEP Intrinsic Value
Not Available
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
51.7%
=
Gross Profit
1.7m
/
Revenue
3.3m
What is the Gross Margin of Euroespes SA?

Based on Euroespes SA's most recent financial statements, the company has Gross Margin of 51.7%.

Back to Top